Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
about
HIV-associated neurocognitive disorder--pathogenesis and prospects for treatmentEfavirenz and the CNS: what we already know and questions that need to be answeredAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.Importance of Drug Pharmacokinetics at the Site of ActionNeurological and psychiatric adverse effects of antiretroviral drugs.Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum.Brain alterations within the first 100 days of HIV infection.Controversies in HIV-associated neurocognitive disordersCortical neurons are a prominent source of the proinflammatory cytokine osteopontin in HIV-associated neurocognitive disordersUnderstanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection.Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and TreatmentPharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patientsComprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyHuman biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.HIV and neurocognitive dysfunction.Neuronal toxicity of efavirenz: a systematic review.Animal models for depression associated with HIV-1 infection.HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Treating HIV Infection in the Central Nervous System.Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.Does efavirenz replacement improve neurological function in treated HIV infection?Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial.Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons.Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.
P2860
Q26766448-EB40C149-4D1C-4197-8B20-A38525705015Q28085028-E3F95CF7-F7CE-442E-A08C-D44B909D2969Q30834094-A5F09629-4242-4ADE-BA40-21419EDFCE04Q33648045-CCEBA869-69D1-40D0-A36A-47C658DFF9A8Q34039419-13707DC6-2B4F-40A7-91F2-FBDBD4AE35C8Q34389419-250ED9F6-8574-42E8-A4A0-D433715E34A3Q34994446-8CB0F706-C01A-4FEF-AB5E-4CBC452AD619Q35037015-5EA2D3E6-542D-4247-8A70-8EF5A0C7A313Q35214668-E6D06336-78BC-41EB-A475-573AAF99970DQ35264787-D8558C2C-A78B-494C-BF4B-43C3386EAD03Q36330202-5A4A0AEB-73B9-4CEF-8B29-0E5597711254Q36554279-59AA3158-7A72-46BA-9F39-B4FE5C71D3DCQ36573340-DD4C1255-D31C-49BC-9C9C-1CCB9D77E984Q36664960-46365675-5D81-4E1D-A4AE-8CBEB403CBE8Q37026878-2224B210-D7DF-4EAF-AAA5-F26778CB789CQ37263885-7C2FF86F-19B4-4D50-9074-263B4A913035Q37635032-D26155B7-F3A0-4209-A2F0-E666715F51A4Q38122104-81D6A06C-8C72-429C-B9C4-771D1875E5D8Q38124394-3462D194-603B-44B7-B961-9FF38005EE80Q38171363-3FADC01D-9D42-49FA-B994-D7BD7BDDF26EQ38444808-8C91CB31-9506-4048-B5CD-F5DE780AABC7Q38645161-C8F09C22-9595-449C-A9FD-2FF68CB79611Q38755666-F0EC2289-4287-48BF-A470-F779B99AE7D2Q38882614-26CC941B-1D80-487E-9127-F7F6724FF7C2Q38921093-AE142FF6-C5F4-4808-938C-0D156A66B99DQ38976612-F1AE7A44-036F-4CF8-8001-3B3600844420Q38987587-B82C790C-0293-4788-8AF1-1328C81B13B2Q39077816-7CBC37EC-DD46-4289-8180-48CA71167070Q39304616-8472353F-AAEB-42AB-8572-399C0D6032D7Q39344476-94A80E03-1A1A-4087-879F-38A03629BA0AQ39364925-7346ED0D-5D7C-4AA0-A4D4-E014EE13563BQ40051820-E7C505F9-2534-4E03-AB9D-CD8142A13DE3Q40129359-75677850-C3DF-412B-A868-85C0AFB57299Q40531475-2E42320F-27A5-4AD1-8821-F76C9B241D45Q40694902-73F32436-C85F-49D4-A6CA-29E54FA65FCFQ41208022-807299CC-155B-42BA-8BB0-6793B623567EQ41602074-1E956221-0331-4F23-BB40-AD089B99C9EBQ41663896-FBEF8968-27D0-46AD-82FC-738DEE6B954BQ42069973-528D7BF4-7BEE-41AC-B927-75E5F29312D8Q42203691-0B0B99AA-7960-4188-A5C2-B31398C45F75
P2860
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@ast
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@en
type
label
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@ast
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@en
prefLabel
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@ast
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@en
P2093
P2860
P356
P1476
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
@en
P2093
Daniel Pomerantz
Justin C McArthur
Lindsay B Avery
Luis B Tovar-y-Romo
Namandjé N Bumpus
Norman J Haughey
P2860
P304
P356
10.1124/JPET.112.195701
P407
P50
P577
2012-09-13T00:00:00Z